Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Global Clean Energy ETF (ICLN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Global Clean Energy ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while iShares Global Clean Energy ETF trades at $18.96. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | ICLN | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $23.75 |
52-Week Low | $10.24 | $13.37 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ICLN, the iShares Global Clean Energy ETF, trades at $19.33, down 1.73% on the day amid a bearish technical signal, with moving averages indicating selling pressure. The fund has gained over 25% year-to-date in 2026, driven by global energy security concerns and investment in renewables, though recent U.S. permit delays and geopolitical tensions pose headwinds. A dividend of $0.06 is scheduled for June 2026.
Outlook remains mixed: strong structural trends support clean energy demand, but policy uncertainty and valuation concerns after recent gains present risks. The ETF offers diversified exposure to global renewables growth, yet investors face volatility from regulatory shifts and competition from other energy sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →
